The Relationship Between Endometrial Thickness and Endometrial Pathology Results in Tamoxifen Users

Background & Objective: As the selective estrogen receptor modulator tamoxifen plays a major role in treating breast cancer, the most common cancer among women globally. Proliferative alterations in the endometrium are among the side effects of tamoxifen therapy. Our study was aimed to evaluate the relationship between endometrial thickness and endometrial pathology results in tamoxifen users. Materials & Methods: This cross-sectional study was conducted at Isfahan between 2022 and 2023. Asymptomatic patients with positive history of breast cancer and tamoxifen usage, underwent vaginal ultrasound and sampling. Samples were sent to pathology laboratory and results were analyzed. Results: A total of 135 females with breast cancer who were taking tamoxifen, participated in this study. According to our findings, there was a significant difference (p=0.015) in the endometrial thickness between the normal group and the two groups of individuals with endometrial cancer and hyperplasia. Also, our data showed that in breast cancer patients, the endometrial thickness with a cut-off of “>14 mm” can significantly predict the risk of endometrial cancer. Conclusion: Our findings indicate that patients with both endometrial cancer and hyperplasia had considerably higher endometrial thickness. Additionally, endometrial thickness with a cut-off of ">14 mm" is a strong predictor of endometrial cancer risk.